- Conditions
- Ocular Graft vs Host Disease, Dry Eye
- Interventions
- rhDNase I, Vehicle
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- oGVHD, Ocular Graft Versus Host Disease
- Interventions
- d-MAPPS™ Ophthalmic Solution, Matching vehicle control
- Biological
- Lead sponsor
- Regenerative Ocular Immunobiologics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Palm Harbor, Florida • Boston, Massachusetts
- Conditions
- oGHVD
- Interventions
- d-MAPPS, Placebo, PI and Patient Masked
- Biological · Other
- Lead sponsor
- Regenerative Ocular Immunobiologics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Huntington Beach, California • Palm Harbor, Florida + 2 more
- Conditions
- Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
- Interventions
- Brimonidine 0.15%, Brimonidine 0.075%, Placebo
- Drug
- Lead sponsor
- Sandeep Jain, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Dry Eye Disease, oGVHD
- Interventions
- The standard care exam and biological specimens' collection
- Diagnostic Test
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Dry Eye
- Interventions
- Intravenous Immune Globulin (IVIG), Placebo
- Drug
- Lead sponsor
- Sandeep Jain, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Graft Versus Host Disease, Ocular Surface Disease, oGVHD, Ocular Graft vs Host Disease, Brimonidine Tartrate, Lubricant Eye Drops, Ophthalmic Solutions, Graft vs Host Disease
- Interventions
- Brimonidine Tartrate, Placebos
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 10 more